Anti-leukemic therapies induce cytogenetic changes of human bone marrow-derived mesenchymal stem cells
| العنوان: | Anti-leukemic therapies induce cytogenetic changes of human bone marrow-derived mesenchymal stem cells |
|---|---|
| المؤلفون: | Li Yuan Bai, Yu Min Liao, Chang Fang Chiu, Ji An Liang, Su-Peng Yeh, Chen Yuan Lin, Wen Jyi Lo, Chiao Lin Lin |
| المصدر: | Annals of Hematology. 91:163-172 |
| بيانات النشر: | Springer Science and Business Media LLC, 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Adult, Male, Oncology, medicine.medical_specialty, Pathology, Allogeneic transplantation, Adolescent, Cyclophosphamide, Karyotype, Antineoplastic Agents, Bone Marrow Cells, Biology, Cytogenetics, Young Adult, Internal medicine, medicine, Humans, Transplantation, Homologous, Chromosome Aberrations, Leukemia, Hematology, Remission Induction, Cell Differentiation, Mesenchymal Stem Cells, General Medicine, Middle Aged, Total body irradiation, Hematopoietic Stem Cells, medicine.disease, Transplantation, medicine.anatomical_structure, Female, Bone marrow, Whole-Body Irradiation, Busulfan, medicine.drug |
| الوصف: | Both bone marrow hematopoietic cells (BM-HCs) and mesenchymal stem cells (BM-MSCs) may have cytogenetic aberrations in leukemic patients, and anti-leukemic therapy may induce cytogenetic remission of BM-HCs. The impact of anti-leukemic therapy on BM-MSCs remains unknown. Cytogenetic studies of BM-MSCs from 15 leukemic patients with documented cytogenetic abnormalities of BM-HCs were investigated. To see the influence of anti-leukemic therapy on BM-MSCs, cytogenetic studies were carried out in seven of them after the completion of anti-leukemic therapy, including anthracycline/Ara-C-based chemotherapy in two patients, high-dose busulfan/cyclophosphamide-based allogeneic transplantation in two patients, and total body irradiation (TBI)-based allogeneic transplantation in three patients. To simulate the effect of TBI in vitro, three BM-MSCs from one leukemic patient and two normal adults were irradiated using the same dosage and dosing schedule of TBI and cytogenetics were re-examined after irradiation. At the diagnosis of leukemia, two BM-MSCs had cytogenetic aberration, which were completely different to their BM-HCs counterpart. After the completion of anti-leukemic therapy, cytogenetic aberration was no longer detectable in one patient. Unexpectedly, BM-MSCs from three patients receiving TBI-based allogeneic transplantation acquired new, clonal cytogenetic abnormalities after transplantation. Similarly, complex cytogenetic abnormalities were found in all the three BM-MSCs exposed to in vitro irradiation. In conclusion, anti-leukemic treatments induce not only "cytogenetic remission" but also new cytogenetic abnormalities of BM-MSCs. TBI especially exerts detrimental effect on the chromosomal integrity of BM-MSCs and highlights the equal importance of investigating long-term adverse effect of anti-leukemic therapy on BM-MSCs as opposed to beneficial effect on BM-HCs. |
| تدمد: | 1432-0584 0939-5555 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84de1caaa5736aeca59e58c86ca1b760Test https://doi.org/10.1007/s00277-011-1254-8Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....84de1caaa5736aeca59e58c86ca1b760 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14320584 09395555 |
|---|